The Biospecimen Core (Core B) provides part of the infrastructure support for Projects 1 - 4. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. The Biospecimen Core is also involved in the maintenance of a large series of prostate cancer xenograft lines developed by Core investigators. These xenografts are used for proposed studies by the POI investigators and each study is overseen by Core personnel. Overall, the operations of this Core group into 4 components: 1. Specimen acquisition, processing, quality control, storage and accessioning into databases; 2. A prostate cancer xenograft maintenance, development and study program. 3. Laboratory services, including interpretation of tissues and tissue localization studies by a urologic pathologist, immunohistochemistry (IHC), quantitative RT-PCR, and immunoassays, i.e, PSA, and tissue culture. The Core will also perform pre-clinical studies using our xenograft resources;and 4. An administrative program to obtain samples from minority patients, prioritize the distribution of specimens, conduct a quality control program, and to ensure patient confidentiality and compliance with IRB requirements. The performance of each of the research projects detailed in this program project mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The investigators directing the Biospecimen Core also make it a policy to provide excess prostate cancer specimen resources to POI collaborators and to non-P01 investigators on a world-wide basis. Overall, the Biospecimen Core is a critical component of this P01 program project.

Public Health Relevance

The Biospecimen Core is not hypothesis driven yet it is an essential component of this POI that enables the investigative teams to conduct hypothesis driven projects. Without adequate specimens and tumor models, both in quantity and quality, the science conducted by these investigators cannot be robust. The Biospecimen Core assures quality research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA163227-02
Application #
8765218
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
2
Fiscal Year
2014
Total Cost
$287,344
Indirect Cost
$29,204
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Liu, Xiaming; Han, Weiwei; Gulla, Sarah et al. (2016) Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer. Prostate 76:649-61
Liu, Xiaming; Han, Weiwei; Gulla, Sarah et al. (2016) Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget 7:1754-64
Li, Zhenfei; Alyamani, Mohammad; Li, Jianneng et al. (2016) Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533:547-51
Kumar, Akash; Coleman, Ilsa; Morrissey, Colm et al. (2016) Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22:369-78
Gao, Shuai; Gao, Yanfei; He, Housheng Hansen et al. (2016) Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep 17:966-976
Penning, Trevor M; Tamae, Daniel (2016) Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer. Curr Opin Endocrinol Diabetes Obes 23:264-70
Asangani, Irfan A; Wilder-Romans, Kari; Dommeti, Vijaya L et al. (2016) BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol Cancer Res 14:324-31
Wu, Yu; Schoenborn, Jamie R; Morrissey, Colm et al. (2016) High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. J Mol Diagn 18:131-43
Mostaghel, Elahe A; Zhang, Ailin; Plymate, Stephen (2016) UDP-glucuronosyltransferase Enzymes in Prostate Cancer Progression: Is Only Androgen Catabolism Involved? Eur Urol 69:610-2
Groner, Anna C; Cato, Laura; de Tribolet-Hardy, Jonas et al. (2016) TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell 29:846-58

Showing the most recent 10 out of 53 publications